ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.411,55
-0,27%
S&P 500
5.321,41
0,25%
US Dollar vs BRL
5,1233
0,37%
Bitcoin
70.123,29
-1,86%
Brent Oil
82,445
-1,30%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. AzurRx BioPharma Inc (AZRX)

  7. AzurRx BioPharma Inc (AZRX) Notícias

AZRX

AzurRx BioPharma (AZRX)

AzurRx BioPharma Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AZRX
DataHoraFonteTítuloCódigoCompanhia
27/06/202318:04Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:AZRXAzurRx BioPharma Inc
23/06/202317:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AZRXAzurRx BioPharma Inc
20/06/202317:26Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:AZRXAzurRx BioPharma Inc
05/06/202308:01Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:AZRXAzurRx BioPharma Inc
15/05/202318:21Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:AZRXAzurRx BioPharma Inc
12/05/202309:33Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AZRXAzurRx BioPharma Inc
05/04/202317:18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AZRXAzurRx BioPharma Inc
04/04/202318:29Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AZRXAzurRx BioPharma Inc
28/03/202307:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AZRXAzurRx BioPharma Inc
23/03/202318:00Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:AZRXAzurRx BioPharma Inc
20/03/202317:11Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AZRXAzurRx BioPharma Inc
09/01/202311:23Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AZRXAzurRx BioPharma Inc
07/12/202218:17Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:AZRXAzurRx BioPharma Inc
28/11/202220:42Edgar (US Regulatory)Securities Registration (section 12(g)) (8-a12g)NASDAQ:AZRXAzurRx BioPharma Inc
11/10/202209:13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:AZRXAzurRx BioPharma Inc
22/09/202209:56Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:AZRXAzurRx BioPharma Inc
25/07/202218:28Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AZRXAzurRx BioPharma Inc
15/07/202217:42Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:AZRXAzurRx BioPharma Inc
17/05/202217:35Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:AZRXAzurRx BioPharma Inc
02/03/202220:02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:AZRXAzurRx BioPharma Inc
01/03/202220:16Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AZRXAzurRx BioPharma Inc
21/09/202113:47GlobeNewswire Inc.AzurRx BioPharma to Change Corporate Name to First Wave BioPharma TodayNASDAQ:AZRXAzurRx BioPharma Inc
14/09/202108:30GlobeNewswire Inc.AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharmaNASDAQ:AZRXAzurRx BioPharma Inc
13/09/202107:00GlobeNewswire Inc.AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease IndicationsNASDAQ:AZRXAzurRx BioPharma Inc
10/09/202113:45GlobeNewswire Inc.AzurRx BioPharma Announces Reverse Stock SplitNASDAQ:AZRXAzurRx BioPharma Inc
10/09/202109:30GlobeNewswire Inc.AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsNASDAQ:AZRXAzurRx BioPharma Inc
09/09/202109:30GlobeNewswire Inc.AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsNASDAQ:AZRXAzurRx BioPharma Inc
07/09/202117:30GlobeNewswire Inc.AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment ConferenceNASDAQ:AZRXAzurRx BioPharma Inc
18/08/202108:05GlobeNewswire Inc.AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)NASDAQ:AZRXAzurRx BioPharma Inc
17/08/202108:00GlobeNewswire Inc.AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819NASDAQ:AZRXAzurRx BioPharma Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AZRX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
PDGR3
PDG REALT ON
BOV
HAGA3
HAGA ON
BOV
INBR32
Inter &
BOV
COGN3
COGNA ON
BOV
SGPS3
SPRINGS ON
BOV
LUPA3
LUPATECH ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
AZEV4
AZEVEDO PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AMAR3
LOJAS MARISA ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
CASH3
Meliuz S.A ON
BOV
GFSA3
GAFISA ON
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados